Form 4 for SUPN SUPERNUS PHARMACEUTICALS, INC.
Accepted 2024-02-26 00:00:00 ET · period of report 2024-02-22 · accession 0001104659-24-027571 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-26 | 2024-02-22 | SUPN | Mottola Frank | SVP, Quality, GMP, Ops, IT | F - Tax | $27.94 | -335 | 6,311 | -5% | -$9,360 |
| D | 2024-02-26 | 2024-02-22 | SUPN | Mottola Frank | SVP, Quality, GMP, Ops, IT | A - Grant | $0.00 | +750 | 6,646 | +13% | $0 |
| DM | 2024-02-26 | 2024-02-22 | SUPN | Mottola Frank | SVP, Quality, GMP, Ops, IT | A - Grant | $0.00 | +31.0K | 990 | New | $0 |
| D | 2024-02-26 | 2024-02-22 | SUPN | Mottola Frank | SVP, Quality, GMP, Ops, IT | D - Sale to Iss | $0.00 | -750 | 1,500 | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-22 | F | D | 335 | $27.94 | 6,311 | D | — | — | (F2) Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. |
| 2 | Common | Common Stock | 2024-02-22 | A | A | 750 | $0.00 | 6,646 | D | — | — | (F1) Includes an aggregate of 215 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. |
| 3 | Derivative | Restricted Stock Unit | 2024-02-22 | A | A | 5,000 | $0.00 | 5,000 | D | — · — to — | 5,000 Common Stock | (F3) Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. (F5) These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025. |
| 4 | Derivative | Employee Stock Option (Right to Buy) | 2024-02-22 | A | A | 25,000 | $0.00 | 25,000 | D | $27.94 · — to 2034-02-22 | 25,000 Common Stock | (F6) The option vests in four equal annual installments beginning on February 22, 2025. |
| 5 | Derivative | Performance Share Unit | 2024-02-22 | A | A | 990 | $0.00 | 990 | D | $0.00 · — to — | 990 Common Stock | (F7) On February 22, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022. |
| 6 | Derivative | Restricted Stock Unit | 2024-02-22 | D | D | 750 | $0.00 | 1,500 | D | — · — to — | 750 Common Stock | (F3) Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. (F4) These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023. |